Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026GlobeNewsWire · Oct 15, 2026
Nautilus Biotechnology Sees Unusually High Options Volume (NASDAQ:NAUT)Defense World · Oct 5, 2026
Neuralink Stock: How to Invest Before the IPOInvestor Place · Oct 2, 2026
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau ProteoformsGlobeNewsWire · Sep 4, 2026
Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent PullbackSeeking Alpha · Aug 3, 2026
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call TranscriptSeeking Alpha · Jul 28, 2026Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 28, 2026 | -$0.14 | -$0.11 | Beat |
| Apr 28, 2026 | -$0.15 | -$0.12 | Beat |
| Feb 26, 2026 | -$0.14 | -$0.11 | Beat |
| Oct 27, 2025 | -$0.15 | -$0.11 | Beat |
| Jul 31, 2025 | -$0.16 | -$0.12 | Beat |
| Apr 29, 2025 | -$0.14 | -$0.13 | Beat |